期刊文献+

p53及CCL2在胃癌组织中的表达及临床意义 被引量:4

Expression and clinical significance of p53 and CCL2 in gastric cancer
下载PDF
导出
摘要 目的探讨肿瘤相关蛋白53(tumor associated protein 53,p53)及CC类趋化因子配体2(CC chemokine ligand 2,CCL2)在胃癌组织中的表达水平及其与胃癌的临床病理特征之间的关系。方法应用免疫组织化学法检测191例胃癌及配对癌旁组织中p53及CCL2蛋白表达,同时将检测结果与临床病理特征进行综合分析。结果胃癌组织中p53及CCL2蛋白表达的阳性率分别为53.9%(103/191)和37.2%(71/191),而在癌旁组织中阳性率分别为14.1%(27/191)和25.1%(48/191)。胃癌组织中p53及CCL2蛋白表达阳性率均高于癌旁组织,差异均具有统计学意义(均P<0.01)。p53蛋白表达在肿瘤分化程度、浸润深度和淋巴结转移方面比较,差异均具有统计学意义(均P<0.05)。CCL2蛋白表达在肿瘤大小、浸润深度和TNM临床分期方面比较,差异均具有统计学意义(均P<0.05)。结论 p53及CCL2蛋白表达情况与胃癌组织生长关系密切,其表达情况可能成为胃癌恶性程度的一个良好指标。 Objective To investigate the expression of tumor associated protein 53( p53) and CC chemokine ligand2( CCL2) in gastric cancer,and to analyze their relationship with the clinical characteristics of gastric cancer. Methods Immunohistochemistry was used to detect the expression of p53 and CCL2 in 191 samples of gastric cancer and matched adjacent tissues,and the correlation of p53 and CCL2 expression with the clinicopathological characteristics of the patients was analyzed. Results Among 191 pairs of specimens,the positive expression rates of p53 and CCL2 protein in gastric cancer tissues were 53. 9%( 103/191) and 37. 2%( 71/191),respectively,whereas those in pericancerous tissues were 14. 1%( 27/191) and 25. 1%( 48/191),respectively( both P 0. 01). The expression of p53 protein was significantly different in terms of tumor differentiation,depth of invasion,and lymph node metastasis( all P 0. 05). The expression of CCL2 was significantly different in terms of tumor size,depth of invasion,and TNM stage( all P 0. 05). Conclusion p53 and CCL2 expression levels are closely correlated with the development of gastric tumor,which can be used as biomarkers for the tumor malignancy of gastric cancer.
作者 姜志新 吴燕剑 Jiang Zhixin;Wu Yanjian(Department of Gastrointestinal Surgery,Shihezi People's Hospital,Shihezi 832000,China)
出处 《实用肿瘤杂志》 CAS 2018年第5期441-444,共4页 Journal of Practical Oncology
关键词 胃肿瘤/病理学 基因 p53 趋化因子CCL2 基因表达 肿瘤抑制蛋白质P53 免疫组织化学 stomach neoplasms/pathology genes p53 chemokine CCL2 gene expression tumor suppressor proteinp53 immunohistochemistry
  • 相关文献

参考文献4

二级参考文献51

  • 1黄志军.食管癌、癌旁组织中P53、MDR-1基因的表达[J].中国老年学杂志,2014,34(7):1782-1784. 被引量:11
  • 2Noushin Taghavi,Firouzeh Biramijamal,Masoud Sotoudeh,Omeed Moaven,Hooman Khademi,Mohammad Reza Abbaszadegan,Reza Malekzadeh.Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients[J].World Journal of Gastroenterology,2010,16(39):4958-4967. 被引量:10
  • 3Grimwade David,Hills Robert K,Moorman Anthony V,Walker Helen,Chatters Stephen,Goldstone Anthony H,Wheatley Keith,Harrison Christine J,Burnett Alan K.Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood . 2010
  • 4Middeke JM,Fang M,Cornelissen JJ,Mohr B,Appelbaum FR,Stadler M,et al.Outcome of patients with abnl (17p)acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood . 2014
  • 5Haaland I,Opsahl JA,Berven FS,Reikvam H,Fredly HK,Haugse R,Thiede B,Mc Cormack E,Lain S,Bruserud O,Gjertsen BT.Molecular mechanisms of nutlin-3 involve acetylation of p53,histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer . 2014
  • 6PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion(J)British Journal of Haematology . 2005 (2)
  • 7Tisato V,Norcio A,Celeghini C,et al.Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. Clinics . 2014
  • 8Ellis Nathan A,Huo Dezheng,Yildiz Ozlem,Worrillow Lisa J,Banerjee Mekhala,Le Beau Michelle M,Larson Richard A,Allan James M,Onel Kenan.MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood . 2008
  • 9Nageswara Rao Dunna,Sugunakar Vure,K. Sailaja.TP53 Codon 72 Polymorphism and Risk of Acute Leukemia. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION . 2012
  • 10Soren Lehmann,Vladimir J. N. Bykov,Dina Ali.Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. Journal of Clinical Oncology . 2012

共引文献22

同被引文献25

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部